402 results about "Steatosis" patented technology

Disclosed herein are pharmaceutical compositions to treat, prevent, reduce the incidence of, or reduce the severity of hepatic steatosis comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the incidence of, or reducing the severity of hepatic steatosis comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

The present disclosure relates to a method. The method includes accessing automatically segmented liver data and automatically segmented spleen data from a patient. The automatically segmented liver data is used to determine a liver attenuation and the automatically segmented spleen data is used to determine a spleen attenuation. A liver-to-spleen attenuation ratio is determined from the liver attenuation and the spleen attenuation. A hepatic steatosis determination is made from the liver-to-spleen attenuation ratio

The invention provides a method and a system for evaluating various liver pathologies based on machine learning. The method comprises the following steps: acquiring weight information, clinical examination information and evaluation results of liver tissue samples of a plurality of historical patients; performing data preprocessing based on the acquired information, and constructing a training set and a test set; training a Logistic regression model and a Ridge regression model by using the training set, determining the performance of the model in predicting balloon sample deformation, fatty degeneration, lobular inflammation, significant fibrosis and NASH, and determining final prediction index parameters and a prediction model; and obtaining weight information, clinical examination information and an evaluation result of the liver tissue sample of the patient, extracting related values of prediction index parameters in the evaluation result, and processing the prediction index parameters by the determined trained prediction model aiming at the corresponding prediction index parameters to obtain a final prediction result. According to the method, the simple model is constructed by obtaining the clinical indexes, and all aspects of the liver pathology of the chronic liver disease can be comprehensively evaluated.

The invention relates to rhodiola rosea pectic polysaccharide and application thereof.The sugar chain structure of the rhodiola rosea pectic polysaccharide is shown in the formula I. In the formula I, Glc is a glucose residue, GalA is a galacturonic acid residue, Ara is an arabinofuranose residue, and MeO is a methoxyl group; wherein m is an integer selected from 10 to 40; n is an integer selected from 1 to 50. The rhodiola rosea pectic polysaccharide can significantly improve mouse liver fatty degeneration induced by high fructose and relieve liver injury, and has a good application prospect in improvement of non-alcoholic fatty liver.

The invention relates to human hepatocyte organoids. In particular, hepatocyte organoids with modified genes involved in lipid homeostasis. The invention also relates to the use of such organoids for modelling diseases involving steatosis. Also included is the use of such organoids as models of fatty liver, such as caused by genetic as well as diet related fatty liver disorders and their use in discovery of novel drugs for treating fatty liver and related disorders. The invention further relates to agents for reducing steatosis in subjects having similar modifications as the hepatocyte organoids of the invention. The invention also relates to methods of reducing or preventing steatosis, treating or preventing cardiovascular disease; treating or preventing NAFLD, and preventing and / or reducing the risk of NASH and / or cirrhosis by increasing FADS2 activity in a subject. Also included is a FADS2 agonist, such as a small molecule, nucleic acid or polypeptide for use in said methods.

The present invention relates to the use of a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone for treating NAFLD / NASH and advanced liver fibrosis by decreased serum cholesterol and triglycerides as well as reducing the content of hepatic fat accumulation, both in the form of macrosteatosis and microsteatosis. Additionally, its use as an agonist for PPARgamma (peroxisome proliferation receptor activated gamma), PPARalpha (peroxisome proliferation receptor activated alpha), LXR and CPT1, key molecules in the metabolism of fatty degradation and inflammation of the liver. In addition, another use is the induction of decreased expression of NFKB master gene, transcriptional inducer of hepatic inflammatory process factor. All of these events results in the reversal of NAFLD / NASH and advanced liver fibrosis.

The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and / or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.

The present invention refers to a system and a method, based on Artificial Intelligence, which automate the estimation of hepatic steatosis on ultrasound images, calculating a quantitative index of hepatic steatosis called KLI (Kidney to Liver Index). The system comprises an ultrasound device connected with processing means designed to implement a method which analyzes the ultrasound images and obtains a quantitative index of said fatty liver disease (KLI - Kidney to Liver Index) through the estimation of the percentage of fat accumulated in the liver, and performs on the ultrasound image a semantic segmentation using an acyclic neural network based on the resnet50 model, from which, through subsequent processing, a degree of hepatic steatosis is defined.

The disclosure provides methods and compositions for treating pancreatic and hepatic disease such as, pancreatic steatosis, pancreatic cancer, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and hepatic cancer. The provided methods include administering an effective amount of a HIF1-α Pathway Inhibitor or a HIF1-α Inhibitor and an PFKFB3 inhibitor to the subject having or at risk of having pancreatic and / or hepatic disease. The provided methods include administering an effective amount of a HIF1-α Pathway Inhibitor or a HIF1-α Inhibitor and an PFKFB3 inhibitor to the subject having or at risk of having pancreatic and / or hepatic disease.

Systems and methods for capturing and processing image data captured by an optical microscope, such as an Open Top Light Sheet (OTLS) microscope are disclosed. Image data can be processed by techniques including flat fielding, image depth correction, and edge correction, and pixel classification and image segmentation techniques can be applied to more accurately identify lipid droplets and fibrous structures for assessment of, for example, steatosis and fibrosis in human liver biopsy tissue samples. Systems and methods are also related to capturing low resolution images of a sample, identifying regions of interest, and then capturing high resolution image of the regions of interest to reduce memory used for storage, increase computation speed, and reduce computational power.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The present invention discloses an image processing-based ultrasonic measurement method for hepatic steatosis. The method comprises preprocessing a set of RF signals from the abdominal region, including the liver, acquired by ultrasound imaging and converting the signals into a grayscale image; processing the grayscale image to obtain a first segmentation template for the liver region; removing interference signal regions from the first segmentation template to obtain a second segmentation template for the liver region; labeling the grayscale image with the second segmentation template to obtain a region of interest; and calculating an attenuation coefficient within the region of interest to characterize the degree of hepatic steatosis. This method allows the attenuation coefficient to be calculated only for sampling points within the liver and non-lesion areas, achieving more accurate hepatic steatosis measurement.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid- and -metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyrate in preparation of a medicine for preventing or treating hepatocellular carcinoma. The invention provides an application of beta-hydroxybutyrate in preparation of a medicine for preventing and / or treating hepatocellular carcinoma. The beta-hydroxybutyrate comprises a beta-hydroxybutyrate or a combination of a plurality of beta-hydroxybutyrates. A series of experimental data show that beta-hydroxybutyrate not only can effectively improve fatty degeneration and inflammatory response of hepatocytes, but also can remarkably reduce the risk of occurrence of metabolic dysfunction related hepatocellular carcinoma (HCC), and can inhibit malignant biological characteristics of HCC. The invention provides a powerful scientific basis for the development of novel HCC prevention and treatment medicines, and has a wide clinical application prospect.

Provided are a GLP-1GIP analog, an FGF21 protein, a trifunctional protein, and use thereof. The trifunctional protein comprises the GLP-1 / GIP analog and the FGF21 protein. Further provided is use of the GLP-1 / GIP analog, the FGF21 protein, and the trifunctional protein in the preparation of a drug for preventing and / or treating diseases related to GLP-1, GIP, and / or FGF21. The provided GLP-1 / GIP analog, FGF21 protein, and trifunctional protein can synergistically regulate blood glucose and lipid levels in vivo, meet multiple needs in patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, promoting weight loss, ameliorating circulating lipid metabolism disorder, etc., and have better biological safety and tolerability and longer in vivo half-lives.

Disclosed in the present invention are a THR-β receptor agonist, a preparation method therefor, and a use method therefor. The present invention provides a compound represented by formula (I), and a pharmaceutically acceptable salt or stereoisomer thereof. The agonist of the present invention has better THR-β agonistic activity and selectivity and strong liver-targeting ability, and can be used in metabolic diseases (such as non-alcoholic steatohepatitis (NASH), hepatic steatosis, hyperlipidemia, and obesity), cardiovascular diseases (such as atherosclerosis), and thyroid diseases (such as hypothyroidism and thyroid cancer).

The invention relates to the field of medicines, in particular to a GLP-1 analogue fusion protein and application thereof. The GLP-1 analogue fusion protein is obtained by fusing GLP-1 at N ends of a heavy chain constant region and a light chain constant region of IgG4. A research result shows that the GLP-1 analogue fusion protein has an obvious effect of reducing the body weight of a mouse, the volume and the weight of the liver of the mouse are reduced, and the NAS score and the liver fatty degeneration are obviously improved. Therefore, the traditional Chinese medicine composition can be applied to medicines or products for slimming or treating fatty liver.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD) is the most common liver disease with a worldwide prevalence estimated at 30% of the general population. To better understand the influence of MASLD progression on cardiovascular disease, the aim of the study was to develop a new physiopathological mouse model able to develop progressive MASLD, along with atherosclerosis development, in a reasonable period of time. LDLr - / - mice were crossed with PPARα-deficient mice in order to obtain LDLr- / - mice expressing (LDLr - / - PPARα + / +) or not (LDLr - / - PPARα - / -) PPARα. Female mice were challenged with a high-fat diet during 12 and 18 weeks. Histological liver analysis showed that, compared to control diet, LDLr - / - PPARα + / + mice under high fat diet developed mostly steatosis at 12 weeks, and then exhibited all characteristics of human MASLD, namely the steatosis, inflammation and ballooning-triad, with presence of fibrosis at 18 weeks. This MASLD progression over time in LDLr - / - PPARα + / + was aggravated in LDLr - / - PPARα + / + mice. The present invenion defines a new relevant mouse model of progressive MASLD, developing all the characteristics of human MASLD (steatosis, inflammation, ballooning, fibrosis), in a relatively short time period (12-18 weeks), along with simultaneous atherosclerosis development.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

An image processing-based method for ultrasonic measurement of hepatic steatosis, comprising: preprocessing a set of RF signals of an abdominal region including a liver region acquired by ultrasonic imaging, and then converting same into a grayscale image (S1); processing the grayscale image to obtain a liver region first segmentation template (S2); removing an interference signal region in the liver region first segmentation template to obtain a liver region second segmentation template (S3); using the liver region second segmentation template to mark the grayscale image, to obtain a region of interest (S4); and in the region of interest, calculating an attenuation coefficient representing the degree of hepatic steatosis (S5). Therefore, the attenuation coefficient can be calculated only for sampling points in the liver and non-focus regions, thereby achieving more accurate hepatic steatosis measurement.

The present application relates to the field of medicine, and specifically to a GLP-1 analog fusion protein and its application. The GLP-1 analog fusion protein is obtained by fusing GLP-1 to the N-terminus of the IgG4 heavy chain constant region and the light chain constant region. The results of the study showed that the GLP-1 analog fusion protein of the present application has a significant effect on reducing the weight of mice. The volume and weight of the mouse liver decreased, and the NAS score and hepatic steatosis were significantly improved. Therefore, the present invention can be applied to drugs or products for weight loss or the treatment of fatty liver.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention discloses a preserving fluid for relieving ischemia-reperfusion injury of transplanted fatty liver, and belongs to the technical field of biomedicine. The invention provides an application of a fibroblast growth factor 21 in preparation of a medicine for preventing and treating liver injury caused by ischemia-reperfusion or a liver transplanted organ preserving fluid. Hepatic cell injury caused by ischemia-reperfusion can be effectively improved through exogenous supplement of the fibroblast growth factor 21; particularly, aiming at the fatty degeneration transplanted liver, the traditional Chinese medicine composition not only can inhibit color tissue damage, cell apoptosis and inflammation caused by ischemia-reperfusion, but also can improve lipid accumulation in the liver, reverse the fatty degeneration of the liver and improve the fatty degeneration donor liver transplantation curative effect.

The invention relates to application of coptis alkaloid in preparation of a medicine for down-regulating liver TREM2 expression, and belongs to the technical field of biological medicine. Animal experiments prove that the rhizoma coptidis alkaloid has the effects of improving liver pathological injury, lipid droplet deposition, liver function impairment, fatty degeneration, iron overload and inflammatory response caused by MASH, and meanwhile, the expression level of TREM2 is improved.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

This invention discloses a low-astringency prickly pear lactic acid bacteria fermented beverage and its application in lowering blood lipids and antioxidation, relating to the fields of microbial application and food fermentation technology. The fermented beverage of this invention uses prickly pear juice as raw material and is prepared by fermentation with *Lactobacillus plantarum* R-21. It can significantly reduce the tannin content of prickly pear juice, improve taste, and increase the polysaccharide content and antioxidant properties of the beverage. In vivo experiments show that it can reduce the levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol in mouse liver and serum, inhibit fat accumulation and fatty degeneration in liver cells, and enhance the activity of antioxidant enzymes in the liver, demonstrating important application value in lowering blood lipids and antioxidation.

The invention discloses a preparation method of an edible flower phenol amide compound and application of the edible flower phenol amide compound in prevention and treatment of non-alcoholic fatty liver disease, and particularly relates to the field of development of new application of food raw materials. The edible flower phenol amide compound N1, N5, N10-coumaroyl spermidine (TCS) can be green extracted by using a natural deep-eutectic solvent (NADES), and can inhibit free fatty acid-induced liver cell lipid accumulation and improve fatty acid-caused liver cell fatty degeneration; oxidative stress and inflammation induced by free fatty acid are inhibited, and expression of senescence-related markers is inhibited, so that development of NAFLD is effectively inhibited.